Drugmakers slash prices to be eligible for China's bulk-buy program
January 18, 2020 at 02:40 AM EST
Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday.